

Raffit Hassan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4316748/publications.pdf>

Version: 2024-02-01

122
papers

10,193
citations

31976

53
h-index

34986

98
g-index

122
all docs

122
docs citations

122
times ranked

8411
citing authors

#	ARTICLE	IF	CITATIONS
1	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3360-3365.	7.1	758
2	Immunotoxin therapy of cancer. Nature Reviews Cancer, 2006, 6, 559-565.	28.4	475
3	Antibody–drug conjugates for cancer therapy. Lancet Oncology, The, 2016, 17, e254-e262.	10.7	439
4	Mesothelin. Clinical Cancer Research, 2004, 10, 3937-3942.	7.0	394
5	Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers. Clinical Cancer Research, 2007, 13, 5144-5149.	7.0	351
6	Immunotoxin Treatment of Cancer*. Annual Review of Medicine, 2007, 58, 221-237.	12.2	340
7	A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction. Clinical Cancer Research, 2012, 18, 858-868.	7.0	304
8	Mesothelin targeted cancer immunotherapy. European Journal of Cancer, 2008, 44, 46-53.	2.8	288
9	Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer. Clinical Cancer Research, 2006, 12, 447-453.	7.0	256
10	Mesothelin Immunotherapy for Cancer: Ready for Prime Time?. Journal of Clinical Oncology, 2016, 34, 4171-4179.	1.6	244
11	Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P. Clinical Cancer Research, 2009, 15, 5274-5279.	7.0	209
12	Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy. Cancer Research, 2014, 74, 2907-2912.	0.9	204
13	Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression. Science Translational Medicine, 2013, 5, 208ra147.	12.4	198
14	Mesothelin Is Overexpressed in Pancreaticobiliary Adenocarcinomas but Not in Normal Pancreas and Chronic Pancreatitis. American Journal of Clinical Pathology, 2005, 124, 838-845.	0.7	197
15	Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers. Clinical Cancer Research, 2010, 16, 6132-6138.	7.0	190
16	Advances in Anticancer Immunotoxin Therapy. Oncologist, 2015, 20, 176-185.	3.7	161
17	Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma. Clinical Cancer Research, 2014, 20, 5927-5936.	7.0	158
18	Localization of Mesothelin in Epithelial Ovarian Cancer. Applied Immunohistochemistry and Molecular Morphology, 2005, 13, 243-247.	1.2	152

#	ARTICLE	IF	CITATIONS
19	Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11782-11787.	7.1	145
20	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for frontâ€line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer, 2014, 120, 3311-3319.	4.1	144
21	A Binding Domain on Mesothelin for CA125/MUC16. Journal of Biological Chemistry, 2009, 284, 3739-3749.	3.4	142
22	Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients. Clinical Cancer Research, 2005, 11, 3814-3820.	7.0	140
23	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma. JAMA Oncology, 2019, 5, 351.	7.1	127
24	Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immunity, 2007, 7, 20.	3.2	127
25	Consensus Report of the 2015 Weinman International Conference on Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 1246-1262.	1.1	122
26	Mesothelin Expression in Human Lung Cancer. Clinical Cancer Research, 2007, 13, 1571-1575.	7.0	118
27	A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice. Gastroenterology, 2014, 146, 1784-1794.e6.	1.3	118
28	Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. American Journal of Clinical Pathology, 2005, 124, 838-45.	0.7	114
29	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9008-9013.	7.1	108
30	Characterization of the B Cell Epitopes Associated with a Truncated Form of <i>Pseudomonas</i> Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients. Journal of Immunology, 2006, 177, 8822-8834.	0.8	104
31	Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8571-8576.	7.1	104
32	First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibodyâ€Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. Journal of Clinical Oncology, 2020, 38, 1824-1835.	1.6	102
33	Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma. Clinical Cancer Research, 2006, 12, 4225-4231.	7.0	101
34	Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncology, The, 2012, 13, e301-e310.	10.7	99
35	Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Annals of the Rheumatic Diseases, 2019, 78, 150-152.	0.9	97
36	Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development. Molecular Cancer Therapeutics, 2012, 11, 517-525.	4.1	96

#	ARTICLE	IF	CITATIONS
37	Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1993-2005.	1.1	96
38	New Insights into Understanding the Mechanisms, Pathogenesis, and Management of Malignant Mesotheliomas. <i>American Journal of Pathology</i> , 2013, 182, 1065-1077.	3.8	91
39	A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 48-57.	4.1	87
40	Scientific Advances and New Frontiers in Mesothelioma Therapeutics. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1269-1283.	1.1	87
41	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	1.1	85
42	Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17099-17104.	7.1	75
43	Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice. <i>Clinical Cancer Research</i> , 2006, 12, 4695-4701.	7.0	73
44	Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2019, 25, 5787-5798.	7.0	72
45	Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. <i>Lung Cancer</i> , 2010, 68, 455-459.	2.0	67
46	High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. <i>Oncotarget</i> , 2015, 6, 11694-11703.	1.8	66
47	New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA. <i>Clinical Cancer Research</i> , 2005, 11, 5840-5846.	7.0	65
48	Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma. <i>Journal of Immunotherapy</i> , 2000, 23, 473-479.	2.4	60
49	Anti-Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts. <i>Clinical Cancer Research</i> , 2007, 13, 7166-7171.	7.0	60
50	Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. <i>Clinical Cancer Research</i> , 2002, 8, 3520-6.	7.0	60
51	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 8034-8034.	1.6	59
52	Identification of Novel Human CTL Epitopes and Their Agonist Epitopes of Mesothelin. <i>Clinical Cancer Research</i> , 2005, 11, 6342-6351.	7.0	56
53	Mesothelin Is Shed from Tumor Cells: Figure 1.. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1751-1751.	2.5	55
54	Chemotherapy and targeted therapies for unresectable malignant mesothelioma. <i>Lung Cancer</i> , 2011, 73, 256-263.	2.0	55

#	ARTICLE	IF	CITATIONS
55	Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1. <i>Clinical Cancer Research</i> , 2004, 10, 16-18.	7.0	51
56	Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression. <i>Journal of Thoracic Oncology</i> , 2020, 15, 843-859.	1.1	51
57	Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?. <i>Frontiers in Oncology</i> , 2020, 10, 343.	2.8	48
58	Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma. <i>Human Pathology</i> , 2018, 71, 1-7.	2.0	46
59	Nonpleural Mesotheliomas: Mesothelioma of the Peritoneum, Tunica Vaginalis, and Pericardium. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 1067-1087.	2.2	45
60	Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts. <i>Clinical Cancer Research</i> , 2011, 17, 3697-3705.	7.0	44
61	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2022, 17, 873-889.	1.1	44
62	Tumor-Directed Radiation and the Immunotoxin SS1P in the Treatment of Mesothelin-Expressing Tumor Xenografts. <i>Clinical Cancer Research</i> , 2006, 12, 4983-4988.	7.0	43
63	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8503-8503.	1.6	43
64	The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy. <i>PLoS ONE</i> , 2011, 6, e14640.	2.5	42
65	Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. <i>Anticancer Research</i> , 2004, 24, 1327-35.	1.1	42
66	Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity. <i>Oncotarget</i> , 2016, 7, 29916-29926.	1.8	41
67	Releasable PEGylation of Mesothelin Targeted Immunotoxin SS1P Achieves Single Dosage Complete Regression of a Human Carcinoma in Mice. <i>Bioconjugate Chemistry</i> , 2007, 18, 773-784.	3.6	40
68	Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. <i>Clinical Cancer Research</i> , 2018, 24, 2859-2872.	7.0	40
69	A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake. <i>Cancer Research</i> , 2010, 70, 1082-1089.	0.9	38
70	New Life for Immunotoxin Cancer Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1055-1058.	7.0	38
71	Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma. <i>Oncotarget</i> , 2017, 8, 26744-26754.	1.8	38
72	Safety and biodistribution of ¹¹¹ In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging. <i>Oncotarget</i> , 2015, 6, 4496-4504.	1.8	38

#	ARTICLE	IF	CITATIONS
73	New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma. Scientific Reports, 2015, 5, 9928.	3.3	37
74	Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors. Molecular Cancer Therapeutics, 2015, 14, 2789-2796.	4.1	34
75	¹¹¹ Indium-labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. , 1999, 80, 559-563.		33
76	Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patientâ€™Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. Clinical Cancer Research, 2017, 23, 1564-1574.	7.0	32
77	Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding. Cancer Research, 2011, 71, 5915-5922.	0.9	31
78	Phase 1 study of the immunotoxin LMBâ€™100 in patients with mesothelioma and other solid tumors expressing mesothelin. Cancer, 2020, 126, 4936-4947.	4.1	31
79	Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells. European Journal of Haematology, 2007, 79, 281-286.	2.2	29
80	Effect of chelator conjugation level and injection dose on tumor and organ uptake of ¹¹¹ In-labeled MORAb-009, an anti-mesothelin antibody. Nuclear Medicine and Biology, 2011, 38, 1119-1127.	0.6	28
81	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and antiâ€™PD-1 antibody in patients with mesothelioma and mouse tumor models. Science Translational Medicine, 2020, 12, .	12.4	28
82	Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. Journal of Nuclear Medicine, 2005, 46, 1201-9.	5.0	26
83	Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR).. Journal of Clinical Oncology, 2016, 34, 2509-2509.	1.6	25
84	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncology, The, 2022, 23, 540-552.	10.7	25
85	Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma. Journal of Thoracic Oncology, 2020, 15, 457-461.	1.1	24
86	Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. BMC Cancer, 2015, 15, 376.	2.6	22
87	Efficacy of antiâ€™insulinâ€™like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factorâ€™ receptor sites/cell. International Journal of Cancer, 2012, 131, 2143-2152.	5.1	20
88	In Vivo Imaging of Human Malignant Mesothelioma Grown Orthotopically in the Peritoneal Cavity of Nude Mice. Journal of Cancer, 2011, 2, 123-131.	2.5	19
89	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. Lung Cancer, 2016, 101, 104-110.	2.0	18
90	Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Research, 2012, 32, 5151-8.	1.1	18

#	ARTICLE	IF	CITATIONS
91	Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1195-1206.	4.1	18
92	Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 737-746.	4.2	17
93	Population pharmacokinetics and exposure–response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 733-743.	2.3	16
94	Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100231.	1.1	16
95	Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 721-5.	2.3	15
96	Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin–targeted therapies. <i>Cancer</i> , 2021, 127, 1010-1020.	4.1	15
97	Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway. <i>Oncotarget</i> , 2017, 8, 87307-87316.	1.8	14
98	Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 246-252.	1.2	12
99	Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors. <i>Oncology Reports</i> , 2012, 27, 1794-800.	2.6	10
100	Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 7030-7030.	1.6	10
101	Targeting mesothelin in ovarian cancer. <i>Oncotarget</i> , 2018, 9, 36050-36051.	1.8	10
102	CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients. <i>Cancer Biology and Therapy</i> , 2018, 19, 622-630.	3.4	9
103	<i>In Vitro</i> and <i>In Vivo</i> Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 316-325.	1.0	9
104	Ex Vivo Cytokine Activation of Peripheral Blood Stem Cells: A Potential Role for Adoptive Cellular Immunotherapy. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 283-290.	1.8	8
105	Inherited predisposition to malignant mesothelioma (MM) due to mutations in DNA repair genes. <i>Journal of Clinical Oncology</i> , 2018, 36, 8504-8504.	1.6	8
106	Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice. <i>PLoS ONE</i> , 2014, 9, e104388.	2.5	8
107	Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2202439119.	7.1	8
108	Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma. <i>JCO Precision Oncology</i> , 2018, 2018, 1-16.	3.0	6

#	ARTICLE	IF	CITATIONS
109	Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer. <i>Journal of applied laboratory medicine</i> , The, 2018, 3, 166-177.	1.3	6
110	A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2511-2511.	1.6	6
111	Advances in diffuse malignant peritoneal mesothelioma. <i>Oncology Reviews</i> , 2007, 1, 53-64.	1.8	5
112	Clinical Features and Outcomes of Tunica Vaginalis Mesothelioma: A Case Series From the National Institutes of Health. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e871-e875.	1.9	4
113	CTLA-4 blockade in mesothelioma: ineffective or reason for optimism?. <i>Lancet Oncology</i> , The, 2017, 18, 1150-1151.	10.7	4
114	¹⁸ F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysisâ€”The Central Role of Volume. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1570-1575.	5.0	4
115	Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN Solid Tumor.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8563-8563.	1.6	4
116	CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8558-8558.	1.6	2
117	Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9093-9093.	1.6	2
118	Immunotherapeutic Approaches to Mesothelioma. <i>Current Cancer Research</i> , 2017, , 347-357.	0.2	0
119	Malignant Mesothelioma. , 2018, , 536-549.e4.		0
120	Reply to D. de Fonseca et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2746-2747.	1.6	0
121	Response to Letter to the Editor by Yang etÂal.. <i>Journal of Thoracic Oncology</i> , 2020, 15, e91.	1.1	0
122	Response to Letter to Editor by Cornelissen etÂal.. <i>Journal of Thoracic Oncology</i> , 2020, 15, e169-e170.	1.1	0